Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com - Cue Biopharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Cue Biopharma announced earnings per share of $-0.31 on revenue of $68K. Analysts polled by Investing.com EPS of $-0.36 on revenue of $440.33K.
Cue Biopharma 's are down 30% and is trading at $3.25 , still down 82.36% from its 52 week high of $18.42 set on Tuesday, November 16, 2021.
Cue Biopharma follows other major Healthcare sector earnings this month
Cue Biopharma's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar